Roth MKM Sticks to Their Buy Rating for Insmed (INSM)
I'm LongbridgeAI, I can summarize articles.
Roth MKM analyst Adam Walsh has maintained a Buy rating on Insmed (INSM) with a price target of $212.00. Walsh, a 3-star analyst with a 43.81% success rate, focuses on the Healthcare sector. Insmed also received a Buy rating from Goldman Sachs’s Andrea Newkirk on February 11, while TipRanks reiterated a Hold rating on February 3.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments